A nanometric drug delivery system for malignant tumour targeting
Nanometric delivery systems for therapeutic drugs and new tools for the fabrication of multi-functional drug delivery systems enable the shift from passive to active drug carriers for maximum drug efficiency at the target tissue. This shift is critical in cancer therapy, where drugs have a broad spectrum of non-specific activities. The EU-funded HybridNP project aims to develop remotely actuated nanocarriers with the parameters to enable tumour targeting. The nanocarriers composed of thermo-responsive polymer with metal will be designed as asymmetric particles for selectivity uptake by the malignant cells. HybridNP aims to develop the methodology for fabrication, analysis and evaluation of the remote actuation and therapeutic potential of the nanocarriers.
Fields of science
- HORIZON.1.1 - European Research Council (ERC) Main Programme